Microbiologics recalled the KWIK-STIK quality control kit on November 13, 2025. The recall affects five units that may have incorrect labeling. This issue may compromise the accuracy of culture media testing for Vibrio parahaemolyticus.
Some products packaged for lot 818-111-7 may have been packaged in pouches labeled as lot 857-53-10.
Patients and healthcare providers should stop using this device immediately. Follow the recall instructions provided by the manufacturer. Contact Microbiologics Inc or your healthcare provider for instructions. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recalled product is the KWIK-STIK quality control kit for culture media, catalog number 0818K. The potentially affected lot number is 818-111-7. The product distributed internationally includes countries such as UAE, China, Singapore, and Kazakhstan.
The recall stems from products packaged under lot number 818-111-7 that may have been incorrectly labeled as lot number 857-53-10. This mislabeling poses a high hazard risk as it could lead to inaccurate testing results.
No specific incidents or injuries have been reported in connection with this recall. The potential for misdiagnosis or incorrect culture results remains a concern.
Stop using the recalled quality control kit immediately. Follow the recall instructions provided by the manufacturer. Contact Microbiologics Inc or your healthcare provider for further instructions.
For more information, call Microbiologics Inc at 1-800-XXXX-XXXX or visit their website at www.microbiologics.com.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.